risperidone · Indivior · NDA 210655
Perseris Kit
Earliest generic entry, as listed · earliest of 2 marketed strengths
13 Feb 2028
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 10010612, US 10376590, US 11013809, US 11712475, US 9180197, US 9186413.
Listed patents · 7 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10010612 | product | 13 Feb 2028 |
| US 10376590 | use U-2608 | 13 Feb 2028 |
| US 11013809 | product, use U-3135 | 13 Feb 2028 |
| US 11712475 | use U-3135 | 13 Feb 2028 |
| US 9180197 | product | 13 Feb 2028 |
| US 9186413 | use U-543 | 13 Feb 2028 |
| US 11110093 | product, use U-3135 | 5 Nov 2026 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 210655 · 001 · RLD · discontinued | for suspension, extended release, subcutaneous | 90MG | 13 Feb 2028 |
| 210655 · 002 · RLD · discontinued | for suspension, extended release, subcutaneous | 120MG | 13 Feb 2028 |
Expired or delisted (3)
- US 10058554 · use U-2363 · 26 Sep 2026
- US 9597402 · product · 26 Sep 2026
- US 10406160 · product, use U-2608 · 26 Jun 2026